Morgan Stanley’s Orphazyme A/S ORPH Stock Holding History

Morgan Stanley’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,342	Closed	-$10K	–	8325
2021 Q4	$10K	Sell	4,342 -2,894	-40%	-$10.2K	﹤0.01%	7486
2021 Q3	$30K	Sell	7,236 -16,164	-69%	-$83.2K	﹤0.01%	6935
2021 Q2	$172K	Buy	+23,400	New	+$189K	﹤0.01%	6088

Other funds holding ORPH

Optiver Holding Amsterdam, Netherlands $371B AUM 64.6% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Morgan Stanley's ORPH Position: Q1 2022 in Review

Morgan Stanley sold out of Orphazyme A/S (ORPH) in Q1 2022, closing a stake of 4,342 shares — an estimated $10K sold.

Morgan Stanley first reported a position in ORPH in Q2 2021 and held it in 3 quarters. The position peaked at $172K in Q2 2021. 4 funds tracked by Wall St. Rank hold ORPH as of Q1 2022.

Morgan Stanley reported no remaining Orphazyme A/S position as of Q1 2022 after selling out during the quarter.
Morgan Stanley sold 4,342 Orphazyme A/S shares in Q1 2022, an estimated $10K.
Morgan Stanley first reported a position in Orphazyme A/S in Q2 2021 and held it in 3 quarters.
Morgan Stanley's Orphazyme A/S position peaked at $172K in Q2 2021.
4 funds tracked by Wall St. Rank held Orphazyme A/S as of Q1 2022.

Based on Morgan Stanley's 13F filing for Q1 2022, filed 13 May 2022.